EFR3A and pancreatic adenocarcinoma: Pancreatic adenocarcinoma appears to be unique among RAS-driven cancers in this regard, as high EFR3A expression was not observed in either other KRAS-driven cancers examined, or cancers driven by mutations in other RAS-isoforms (Supplementary Fig. 3a).